Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes

Press/Media

Period1 Sep 2022

Media coverage

1

Media coverage

  • TitleBayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes
    Media name/outletBiotechnologyNewsMagazine.InfomeddNews.com
    Country/TerritoryUnited States
    Date1/09/22
    URLhttps://biomag1.com/bayers-kerendia-finerenone/
    PersonsSameer Bansilal
View all 1
View less